Within the United Kingdom, a new vaccine is already in the testing phase that seeks to be used for the treatment of multiple types of cancer, including prostate, lung and ovarian cancer.
The vaccine is called OVM-200 and is developed by Oxford Vacmedix, which is a company created by scientists who graduated from the University of Oxford in the British territory.
It was in august 2021 when the company received regulatory approval by the Medicines and Health Products Regulatory Authority (MHRA for its acronym in English) to start with your essays.
HOW DOES THIS VACCINE WORK?
The company Oxford Vacmedix uses a new patented technology of recombinant overlapping peptides (ROP) that have been validated as a technology for stimulate broad and strong T-cell immunitywhich is why it is seen as a good platform for the development of cancer therapies.
In this way, the vaccine that was developed indicates to the immune system the specific protein to attack and that usually protects cancer cells.
The protein is known as survivina and is usually located in the surface of cells of many types of cancer in large numbers and serves as the main protection against attacks by the immune system.
To work, the vaccine OVM-200 has a synthetic form of survivin which is designed to stimulate the response of the immune system and thereby eliminate cancer cells.
Scientists point out that in this way they can create treatments with greater efficacy, lower costs, simpler regulatory pathways and synergy when used in combination with other immune oncology agents.
“With this trial we are looking at three types of cancer with high unmet clinical need,” explained Tom Morris, medical director of Oxford Vacmedix when the project was approved. “We see the potential benefits of a vaccination approach both in stimulating the body’s immune system to attack cancer and, in future trials, in improving the efficacy of immune oncology agents.”
The importance of the project within the United Kingdom it is because the prostate, lung and ovarian cancers are the death cause of at least 51,000 personas on British soil and represent at least and third of all cancer deaths.
HOW IS THE STUDY DONE?
It was in November 2021 that the study began in its Phase 1 and with tests for the first time in humans. For this, it took up to 52 patients from 18 to 75 years old who suffer from cancer such as prostate, lung and ovary.
The first phase is divided into two parts, the first with a dose increase when evaluated to four increasing doses of OVM-200 in small groups of cancer patients to find the recommended dose to apply. Afterwards, the recommended dose will be administered to cancer patients in the expansion part to confirm your security, how effective is and his side effects.
The patients who are part of the study will receive 3 doses of the vaccine in two week intervals and, upon completion of treatment, they will be followed up to monitor changes in both you and your cancer.
The study runs in at least five sites in the UK and the patients who are part of it will remain under evaluation for six monthstime in which they will have to perform at least 10 hospital visits.
In this way, primary completion of the study is expected to be achieved by December 31, 2022 and the estimated date for completion of the study is January 31, 2023. Although the study of vaccine focuses on three types of cancersscientists say it could be effective against multiple types if its effectiveness is verified.
Originally published in The Sun of Mexico
–
